Clinical Efficacy and Safety of Nivolumab: Results of a Multicenter, Open-label, Single-arm, Japanese Phase II study in Malignant Pleural Mesothelioma (MERIT).
Morihito OkadaTakashi KijimaKeisuke AoeTerufumi KatoNobukazu FujimotoKazuhiko NakagawaYuichiro TakedaToyoaki HidaKuninobu KanaiFumio ImamuraSatoshi OizumiToshiaki TakahashiMitsuhiro TakenoyamaHiroshi TanakaJun HiranoYoshinobu NambaYuichiro OhePublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)
Nivolumab met the primary endpoint as second- or third-line treatment for patients with MPM and showed promising efficacy with manageable toxicity.See related commentary by Mansfield and Zauderer, p. 5438.